Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal
  • TA1076
  • Published: 

History

Documents created during the development process.

Draft guidance: 1

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6339

Topic selection